- Home
- SCNX vs AKTX Comparison
SCNX vs AKTX Comparison
Compare SCNX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- AKTX
- Stock Information
- Founded
- SCNX 2010
- AKTX N/A
- Country
- SCNX United States
- AKTX United States
- Employees
- SCNX N/A
- AKTX N/A
- Industry
- SCNX Other Pharmaceuticals
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- AKTX Health Care
- Exchange
- SCNX Nasdaq
- AKTX Nasdaq
- Market Cap
- SCNX 21.2M
- AKTX 35.7M
- IPO Year
- SCNX 2020
- AKTX N/A
- Fundamental
- Price
- SCNX $2.13
- AKTX $1.11
- Analyst Decision
- SCNX
- AKTX Strong Buy
- Analyst Count
- SCNX 0
- AKTX 1
- Target Price
- SCNX N/A
- AKTX $5.00
- AVG Volume (30 Days)
- SCNX 240.1K
- AKTX 17.3K
- Earning Date
- SCNX 08-10-2025
- AKTX 08-18-2025
- Dividend Yield
- SCNX N/A
- AKTX N/A
- EPS Growth
- SCNX N/A
- AKTX N/A
- EPS
- SCNX N/A
- AKTX N/A
- Revenue
- SCNX $146,901.00
- AKTX N/A
- Revenue This Year
- SCNX N/A
- AKTX N/A
- Revenue Next Year
- SCNX N/A
- AKTX N/A
- P/E Ratio
- SCNX N/A
- AKTX N/A
- Revenue Growth
- SCNX N/A
- AKTX N/A
- 52 Week Low
- SCNX $0.69
- AKTX $0.85
- 52 Week High
- SCNX $23.77
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- AKTX 43.71
- Support Level
- SCNX N/A
- AKTX $1.08
- Resistance Level
- SCNX N/A
- AKTX $1.15
- Average True Range (ATR)
- SCNX 0.00
- AKTX 0.03
- MACD
- SCNX 0.00
- AKTX 0.00
- Stochastic Oscillator
- SCNX 0.00
- AKTX 39.12
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.